Children with CBR gene variations who are given anthracycline chemotherapy for cancer have a higher risk of developing heart disease later in life, a study found. Researchers said the data could one day help doctors screen children for the variation and offer alternative therapies that don't damage the heart.

Full Story:
HealthDay News

Related Summaries